Literature DB >> 19167079

The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes.

Ronald Klein1, Michael D Knudtson, Kristine E Lee, Ronald Gangnon, Barbara E K Klein.   

Abstract

OBJECTIVE: To examine the 25-year cumulative incidence of macular edema (ME) and its relation to various risk factors.
DESIGN: Population-based study. PARTICIPANTS: A total of 955 insulin-taking persons living in an 11-county area in southern Wisconsin with type 1 diabetes diagnosed before age 30 years who participated in baseline examinations (1980-1982) and at least 1 of 4 follow-up (4-, 10-, 14-, and 25-year) examinations (n=891) or died before the first follow-up examination (n=64).
METHODS: Stereoscopic color fundus photographs were graded using the modified Airlie House classification and the Early Treatment Diabetic Retinopathy Study retinopathy severity scheme. Competing risk of death was included in statistical models. MAIN OUTCOME MEASURES: Incidence of ME and clinically significant ME (CSME).
RESULTS: The 25-year cumulative incidence was 29% for ME and 17% for CSME. Annualized incidences of ME were 2.3%, 2.1%, 2.3%, and 0.9% in the first, second, third, and fourth follow-up periods of the study, respectively. In univariate analyses, the incidence of ME was associated with male sex, more severe diabetic retinopathy, higher glycosylated hemoglobin, proteinuria, higher systolic and diastolic blood pressure, and more pack-years of smoking. Multivariate analyses showed that the incidence of ME was related to higher baseline glycosylated hemoglobin (hazard ratio [HR] per 1% 1.17; 95% confidence interval [CI], 1.10-1.25; P<0.001) and higher systolic blood pressure (HR per 10 mmHg 1.15; 95% CI, 1.04-1.26; P=0.004) and marginally to proteinuria (HR 1.43; 95% CI, 0.99-2.08; P=0.06).
CONCLUSIONS: These data show that relatively high 25-year cumulative rates of incidence of ME were related to glycemia and blood pressure. The lower risk of incident ME in the last period of the study may reflect recent improvement in care.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19167079      PMCID: PMC2693093          DOI: 10.1016/j.ophtha.2008.10.016

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  49 in total

1.  Is diabetic retinopathy an inflammatory disease?

Authors:  A P Adamis
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  The hypertension detection and follow-up program: Hypertension detection and follow-up program cooperative group.

Authors: 
Journal:  Prev Med       Date:  1976-06       Impact factor: 4.018

3.  Smoking, platelets and thrombosis.

Authors:  R I Hawkins
Journal:  Nature       Date:  1972-04-28       Impact factor: 49.962

4.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Authors:  John M Lachin; Saul Genuth; Patricia Cleary; Matthew D Davis; David M Nathan
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

5.  A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes.

Authors:  Biljana Miljanovic; Robert J Glynn; David M Nathan; Joann E Manson; Debra A Schaumberg
Journal:  Diabetes       Date:  2004-11       Impact factor: 9.461

6.  Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.

Authors:  Peter Hovind; Lise Tarnow; Kasper Rossing; Peter Rossing; Stefanie Eising; Nicolai Larsen; Christian Binder; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

7.  Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy.

Authors:  Barbara E K Klein; Ronald Klein; Patrick E McBride; Karen J Cruickshanks; Mari Palta; Michael D Knudtson; Scot E Moss; Jennifer O Reinke
Journal:  Arch Intern Med       Date:  2004-09-27

8.  Risk factors for diffuse and focal macular edema.

Authors:  Pedro Romero Aroca; Mercè Salvat; Juan Fernández; Isabel Méndez
Journal:  J Diabetes Complications       Date:  2004 Jul-Aug       Impact factor: 2.852

Review 9.  Epidemiology of diabetic retinopathy and macular oedema: a systematic review.

Authors:  R Williams; M Airey; H Baxter; J Forrester; T Kennedy-Martin; A Girach
Journal:  Eye (Lond)       Date:  2004-10       Impact factor: 3.775

10.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes.

Authors:  Ronald Klein; Michael D Knudtson; Kristine E Lee; Ronald Gangnon; Barbara E K Klein
Journal:  Ophthalmology       Date:  2008-11       Impact factor: 12.079

View more
  105 in total

1.  Predictors of adherence with self-care guidelines among persons with type 2 diabetes: results from a logistic regression tree analysis.

Authors:  Takashi Yamashita; Cary S Kart; Douglas A Noe
Journal:  J Behav Med       Date:  2011-12-13

Review 2.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

3.  Plasma kallikrein and diabetic macular edema.

Authors:  Edward P Feener
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

4.  Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis.

Authors:  Xiao-Ling Zhang; Jian Chen; Ri-Jia Zhang; Wen-Jie Wang; Qing Zhou; Xiao-Yan Qin
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

5.  Current status in diabetic macular edema treatments.

Authors:  Pedro Romero-Aroca
Journal:  World J Diabetes       Date:  2013-10-15

6.  Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.

Authors:  Ashay D Bhatwadekar; Viral S Kansara; Thomas A Ciulla
Journal:  Expert Opin Investig Drugs       Date:  2020-01-31       Impact factor: 6.206

7.  Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial.

Authors:  Homayoun Nikkhah; Reza Niazpour Moez; Morteza Entezari; Alireza Ramezani; Kiana Hassanpour; Saeed Karimi; Mehdi Yaseri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-15       Impact factor: 3.117

8.  Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis.

Authors:  Tian-Wei Qian; Meng-Ya Zhao; Xin-Xin Li; Xun Xu
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

9.  Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study.

Authors:  Ashish Sharma; Keerthi Bellala; Pankaj Dongre; Prahalad Reddy
Journal:  Int Ophthalmol       Date:  2019-08-03       Impact factor: 2.031

10.  Current treatments in diabetic macular oedema: systematic review and meta-analysis.

Authors:  John Alexander Ford; Noemi Lois; Pamela Royle; Christine Clar; Deepson Shyangdan; Norman Waugh
Journal:  BMJ Open       Date:  2013-03-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.